D-0837-2022 Class II Terminated
FDA drug recall D-0837-2022 was initiated by Macleods Pharma Usa Inc on Apr 15, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated Oct 13, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- May 11, 2022
- Initiation Date
- Apr 15, 2022
- Termination Date
- Oct 13, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Losartan Potassium & Hydrochlorothiazide Tablets, USP, 100 mg/12.5 mg, a) 30-count bottles (NDC# 33342-051-07), b) 90-count bottles (NDC # 33342-051-10) c) 1000-count bottles (NDC # 33342-051-44), Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536
Reason for recall
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Distribution pattern
Product was distributed nationwide.
Code information
Lot # BLL2107B, exp. date 05/2023 BLL2101A, exp. date 01/2025 BLL2102A, exp. date 02/2025 BLL2103B, exp. date 02/2023 BLL2104A, exp. date 05/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0837-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026